Intravesical chemotherapy involves a healthcare professional injecting chemotherapy medication directly into the bladder to treat cancerous tumors. “Intravesical” means “within the bladder.” ...
In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...
Clinical utility of urine tumor DNA in bladder cancer patients. TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the first patient in the United States with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...
Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in ...
Effect of digital Ki67-based risk modeling on prognostic precision in non–muscle-invasive bladder cancer and high-risk subsets in mixed-grade tumors. Prospective multicenter development and external ...
Neoadjuvant mitomycin C showed a favorable safety profile with mild to moderate side effects, including hematuria, dysuria, and itchy scalp. The trial did not show significant improvement in 12-month ...
UGN-102 could become the first FDA-approved treatment for low-grade intermediate-risk non-muscle-invasive bladder cancer, with a PDUFA goal date of June 13, 2025. The phase 3 ENVISION trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results